Patient | Age (years) | Sex | Diagnosis | MK-2206 dose | Prior lines of therapy | Trastuzumab-free interval (days) | Reason for discontinuing prior trastuzumab | Time to progressive disease/withdrawal (days) | Best response |
---|---|---|---|---|---|---|---|---|---|
A | 40 to 49 | Female | Breast cancer | 60 mg QOD | 5 | 41 | Progressive disease | 167 | SD (unconfirmed PR) |
B | 50 to 59 | Female | Breast cancer | 60 mg QOD | 4 | 21 | Progressive disease | 164 | SD |
C | 50 to 59 | Male | Gastric cancer | 200 mg QW | 2 | 0 | Trastuzumab not given | 171 | SD |
D | 50 to 59 | Female | Breast cancer | 60 mg QOD | 8 | 48 | Unknown | 219 | SD |
E | 40 to 49 | Female | Breast cancer | 135 mg QW | 5 | 68 | Completed therapy | 105 | SD |
F | 50 to 59 | Female | Breast cancer | 60 mg QOD | 3 | 0 | Progressive disease | 388 (withdraw)a | PR |
7 | 50 to 59 | Female | Breast cancer | 135 mg QW | 5 | 28 | Progressive disease | 106 (withdraw) | CR |